---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-106975"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2024-04-23T23:59:59+00:00"
generated_at: "2026-06-03T12:25:02.490219+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology raises $1.0M via private placement of 494,096 shares at $2.034/sh and warrants

## Summary
- Gross proceeds $1.0M from sale of 494,096 shares at $2.034/sh and warrants to purchase same number at $2.26.
- Director Stan Smith purchased 147,492 shares/warrants for ~$300k; Louie Ngar Yee purchased 19,665 for ~$40k.
- Warrants exercisable at $2.26, commencing 6 months from issuance, term 5 years.
- Net proceeds to fund first third of THIO-101 Part C trial for non-small cell lung cancer.
- Closing expected on or about April 25, 2024.

## SEC filing metadata
- accession: 0001193125-24-106975
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2024-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312524106975/0001193125-24-106975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312524106975/d815817d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-106975
- JSON: https://secwatch.observer/filing/0001193125-24-106975.json
- Plain text: https://secwatch.observer/filing/0001193125-24-106975.txt

## Key facts
- Material Agreements
  MAIA Biotechnology, Inc. entered into "Purchase Agreement" with certain accredited investors valued at aggregate purchase price of approximately $664,994 (effective 2024-04-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: aggregate purchase price of approximately $664,994
  - Effective: 2024-04-22
  source text: On April 22, 2024, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 326,939 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 326,939 shares of Common Stock, at a price per share of $2.034, for an aggregate purchase price of approximately $664,994.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312524106975/0001193125-24-106975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.